Home › Compare › GDNEF vs ABBV
GDNEF yields 245.70% · ABBV yields 3.06%● Live data
📍 GDNEF pulled ahead of the other in Year 1
Combined, GDNEF + ABBV cover 0 of 12 months — good coverage
Which stock is actually better after tax? Adjust your rate to find out.
What's the optimal mix of GDNEF + ABBV for your $10,000?
Golden Eagle Retail Group Limited, an investment holding company, engages in development and operation of lifestyle center and stylish department stores in the People's Republic of China. The company operates through three segments: Retail Operations; Property Development and Hotel Operations; and Other Operations. It also operates supermarkets and hotels. As of December 31, 2021, the company operated 31 self-owned stores with a total gross floor area of 2,529,930 square meters and a total operating area of 1,713,415 square meters; and 15 lifestyle centers with a total gross floor area of 1,971,090 square meters in the People's Republic of China. In addition, it engages in online trading activities; property holding; operation of aquariums; and trading of cosmetic products. Further, the company is involved in the property development and investment activities. Additionally, it offers communication and information services, as well as invests in education services. The company is headquartered in Nanjing, China. Golden Eagle Retail Group Limited is a subsidiary of Golden Eagle International Retail Group Limited.
Full GDNEF Calculator →AbbVie Inc. discovers, develops, manufactures, and sells pharmaceuticals in the worldwide. The company offers HUMIRA, a therapy administered as an injection for autoimmune and intestinal Behçet's diseases; SKYRIZI to treat moderate to severe plaque psoriasis in adults; RINVOQ, a JAK inhibitor for the treatment of moderate to severe active rheumatoid arthritis in adult patients; IMBRUVICA to treat adult patients with chronic lymphocytic leukemia (CLL), small lymphocytic lymphoma (SLL), and VENCLEXTA, a BCL-2 inhibitor used to treat adults with CLL or SLL; and MAVYRET to treat patients with chronic HCV genotype 1-6 infection. It also provides CREON, a pancreatic enzyme therapy for exocrine pancreatic insufficiency; Synthroid used in the treatment of hypothyroidism; Linzess/Constella to treat irritable bowel syndrome with constipation and chronic idiopathic constipation; Lupron for the palliative treatment of advanced prostate cancer, endometriosis and central precocious puberty, and patients with anemia caused by uterine fibroids; and Botox therapeutic. In addition, the company offers ORILISSA, a nonpeptide small molecule gonadotropin-releasing hormone antagonist for women with moderate to severe endometriosis pain; Duopa and Duodopa, a levodopa-carbidopa intestinal gel to treat Parkinson's disease; Lumigan/Ganfort, a bimatoprost ophthalmic solution for the reduction of elevated intraocular pressure (IOP) in patients with open angle glaucoma (OAG) or ocular hypertension; Ubrelvy to treat migraine with or without aura in adults; Alphagan/ Combigan, an alpha-adrenergic receptor agonist for the reduction of IOP in patients with OAG; and Restasis, a calcineurin inhibitor immunosuppressant to increase tear production, as well as other eye care products. AbbVie Inc. has a research collaboration with Dragonfly Therapeutics, Inc. The company was incorporated in 2012 and is headquartered in North Chicago, Illinois.
Full ABBV Calculator →Save your analysis + weekly dividend insights. Free forever.
⚠️ Educational purposes only. Not financial advice. Congressional trades sourced from SEC STOCK Act filings via FMP. Past performance does not guarantee future results.